What stage of kidney disease corresponds to a Glomerular Filtration Rate (GFR) of 58?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 28, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Stage 3a Chronic Kidney Disease

A GFR of 58 mL/min/1.73 m² corresponds to Stage 3a chronic kidney disease, defined as moderately decreased kidney function with GFR between 45-59 mL/min/1.73 m². 1, 2

Understanding the Classification

The KDIGO classification system subdivides Stage 3 CKD into two distinct categories because mortality and adverse outcome risks differ substantially between these subgroups 1, 2:

  • Stage 3a: GFR 45-59 mL/min/1.73 m² (your patient falls here)
  • Stage 3b: GFR 30-44 mL/min/1.73 m²

This subdivision is clinically important because Stage 3b patients demonstrate significantly higher risks of progression to kidney failure and cardiovascular events compared to Stage 3a patients 1, 3.

Critical Diagnostic Requirement

A single GFR measurement of 58 does not establish chronic kidney disease. The diagnosis requires abnormalities to be present for >3 months to distinguish CKD from acute kidney injury 1, 2, 4. You must either:

  • Review historical eGFR measurements showing persistent reduction, OR
  • Repeat serum creatinine and eGFR measurement after 3 months to confirm chronicity 4

Essential Next Step: Measure Albuminuria

Immediately measure urine albumin-to-creatinine ratio (UACR) on a random spot urine sample 1, 2, 4. The combination of GFR and albuminuria determines:

  • Risk stratification for progression and cardiovascular events 1, 4
  • Treatment intensity and monitoring frequency 2
  • Need for nephrology referral 2

Albuminuria categories are 1, 4:

  • A1: <30 mg/g (normal to mildly increased)
  • A2: 30-300 mg/g (moderately increased)
  • A3: >300 mg/g (severely increased)

Immediate Clinical Actions

Medication Review

Review and adjust all renally-cleared medications at this GFR level, as drug accumulation can occur with reduced kidney function 2.

Blood Pressure Management

  • Target BP ≤140/90 mmHg if UACR <30 mg/g 2
  • Target BP <130/80 mmHg if any degree of albuminuria is present 2
  • Initiate ACE inhibitor or ARB if the patient has diabetes with hypertension and any degree of albuminuria 2

Cardiovascular Risk Reduction

Patients with Stage 3a CKD face a 2- to 4-fold increased cardiovascular risk compared to those without CKD 2. Address all modifiable cardiovascular risk factors aggressively.

Lifestyle Modifications

Implement sodium restriction, regular physical activity, smoking cessation, and weight management 2.

Monitoring Strategy

For Stage 3a with normal albuminuria (A1): Monitor eGFR and UACR annually 2

For Stage 3a with moderately increased albuminuria (A2): Monitor 2-3 times yearly 2

For Stage 3a with severely increased albuminuria (A3): Monitor 3-4 times yearly and refer to nephrology 2

Nephrology Referral Indications

Nephrology referral is NOT necessary for Stage 3a CKD with normal albuminuria and stable function 2. However, refer if 2:

  • Severely increased albuminuria (≥300 mg/g) is present
  • Rapid decline in eGFR occurs
  • Uncertainty about the underlying cause exists
  • Difficulty managing CKD complications arises

Common Pitfall to Avoid

Do not rely on serum creatinine alone. Serum creatinine underestimates CKD in 80.6% of older adults with Stage 3 disease who have creatinine values ≤1.5 mg/dl 5. Always calculate eGFR using validated equations (CKD-EPI 2021) 2, 4.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Chronic Kidney Disease Stage 3a Classification and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Diagnosis and Evaluation of Chronic Kidney Disease

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.